全文获取类型
收费全文 | 114717篇 |
免费 | 8427篇 |
国内免费 | 389篇 |
专业分类
耳鼻咽喉 | 1338篇 |
儿科学 | 2956篇 |
妇产科学 | 1678篇 |
基础医学 | 15142篇 |
口腔科学 | 1505篇 |
临床医学 | 11758篇 |
内科学 | 25551篇 |
皮肤病学 | 1447篇 |
神经病学 | 10889篇 |
特种医学 | 4210篇 |
外国民族医学 | 1篇 |
外科学 | 17754篇 |
综合类 | 1349篇 |
一般理论 | 108篇 |
预防医学 | 8884篇 |
眼科学 | 2747篇 |
药学 | 7966篇 |
1篇 | |
中国医学 | 154篇 |
肿瘤学 | 8095篇 |
出版年
2023年 | 823篇 |
2022年 | 1274篇 |
2021年 | 2999篇 |
2020年 | 1721篇 |
2019年 | 2789篇 |
2018年 | 3242篇 |
2017年 | 2334篇 |
2016年 | 2475篇 |
2015年 | 2835篇 |
2014年 | 4213篇 |
2013年 | 5551篇 |
2012年 | 8735篇 |
2011年 | 9058篇 |
2010年 | 4986篇 |
2009年 | 4423篇 |
2008年 | 7630篇 |
2007年 | 8068篇 |
2006年 | 7715篇 |
2005年 | 7577篇 |
2004年 | 7017篇 |
2003年 | 6556篇 |
2002年 | 6072篇 |
2001年 | 871篇 |
2000年 | 609篇 |
1999年 | 918篇 |
1998年 | 1278篇 |
1997年 | 968篇 |
1996年 | 834篇 |
1995年 | 775篇 |
1994年 | 717篇 |
1993年 | 681篇 |
1992年 | 483篇 |
1991年 | 376篇 |
1990年 | 356篇 |
1989年 | 326篇 |
1988年 | 316篇 |
1987年 | 304篇 |
1986年 | 276篇 |
1985年 | 320篇 |
1984年 | 456篇 |
1983年 | 392篇 |
1982年 | 576篇 |
1981年 | 516篇 |
1980年 | 418篇 |
1979年 | 209篇 |
1978年 | 279篇 |
1977年 | 254篇 |
1976年 | 215篇 |
1975年 | 167篇 |
1974年 | 145篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
1.
2.
Kara S. Tanaka MD Veronica R. Andaya BA Steven W. Thorpe MD Kenneth R. Gundle MD James B. Hayden MD Yee-Cheen Duong MD Raffi S. Avedian MD David G. Mohler MD Lee J. Morse MD Melissa N. Zimel MD Richard J. O'Donnell MD Andrew Fang MD Robert Lor Randall MD Tina H. Tran BS Christin New BA Rosanna L. Wustrack MD other members of Study Group FORCE 《Journal of surgical oncology》2023,127(1):148-158
3.
Triposkiadis Filippos Xanthopoulos Andrew Skoularigis John Starling Randall C. 《Heart failure reviews》2022,27(6):1991-2003
Heart Failure Reviews - The nitric oxide (NO)–guanylate cyclase (GC)–cyclic guanosine monophosphate (cGMP) pathway plays an important role in cardiovascular, pulmonary and renal... 相似文献
4.
5.
6.
7.
8.
9.
William R. C. Knight Cara R. Baker Nyree Griffin Wahyu Wulaningsih Mark Kelly Andrew R. Davies James A. Gossage 《British journal of cancer》2021,124(10):1653
Background A high Mandard score implies a non-response to chemotherapy in oesophageal adenocarcinoma. However, some patients exhibit tumour volume reduction and a nodal response despite a high score. This study examines survival and recurrence patterns in these patients.Methods Clinicopathological factors were analysed using multivariable Cox regression assessing time to death and recurrence. Computed tomography-estimated tumour volume change was examined in a subgroup of consecutive patients.Results Five hundred and fifty-five patients were included. Median survival was 55 months (Mandard 1–3) and 21 months (Mandard 4 and 5). In the Mandard 4 and 5 group (332 patients), comparison between complete nodal responders and persistent nodal disease showed improved survival (90 vs 18 months), recurrence rates (locoregional 14.75 vs 28.74%, systemic 24.59 vs 48.42%) and circumferential resection margin positivity (22.95 vs 68.11%). Complete nodal response independently predicted improved survival (hazard ratio 0.34 (0.16–0.74). Post-chemotherapy tumour volume reduction was greater in patients with a complete nodal response (−16.3 vs −7.7 cm3, p = 0.033) with no significant difference between Mandard groups.Conclusion Patients with a complete nodal response to chemotherapy have significantly improved outcomes despite a poor Mandard score. High Mandard score does not correspond with a non-response to chemotherapy in all cases and patients with nodal downstaging may still benefit from adjuvant chemotherapy.Subject terms: Oesophageal cancer, Surgical oncology 相似文献
10.
Edward J. Holland Walter O. Whitley Kenneth Sall Stephen S. Lane Aparna Raychaudhuri Steven Y. Zhang 《Current medical research and opinion》2016,32(10):1759-1765
Objective: Report efficacy findings from three clinical trials (one phase 2 and two phase 3 [OPUS-1, OPUS-2]) of lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease (DED).Research design and methods: Three 84-day, randomized, double-masked, placebo-controlled trials. Adults (≥18 years) with DED were randomized (1:1) to lifitegrast 5.0% or matching placebo. Changes from baseline to day 84 in signs and symptoms of DED were analyzed.Main outcome measures: Phase 2, pre-specified endpoint: inferior corneal staining score (ICSS; 0–4); OPUS-1, coprimary endpoints: ICSS and visual-related function subscale (0–4 scale); OPUS-2, coprimary endpoints: ICSS and eye dryness score (EDS, VAS; 0–100).Results: Fifty-eight participants were randomized to lifitegrast 5.0% and 58 to placebo in the phase 2 trial; 293 to lifitegrast and 295 to placebo in OPUS-1; 358 to lifitegrast and 360 to placebo in OPUS-2. In participants with mild-to-moderate baseline DED symptomatology, lifitegrast improved ICSS versus placebo in the phase 2 study (treatment effect, 0.35; 95% CI, 0.05–0.65; p?=?0.0209) and OPUS-1 (effect, 0.24; 95% CI, 0.10–0.38; p?=?0.0007). Among more symptomatic participants (baseline EDS ≥40, recent artificial tear use), lifitegrast improved EDS versus placebo in a post hoc analysis of OPUS-1 (effect, 13.34; 95% CI, 2.35–24.33; nominal p?=?0.0178) and in OPUS-2 (effect, 12.61; 95% CI, 8.51–16.70; p?<?0.0001).Limitations: Trials were conducted over 12 weeks; efficacy beyond this period was not assessed.Conclusions: Across three trials, lifitegrast improved ICSS in participants with mild-to-moderate baseline symptomatology in two studies, and EDS in participants with moderate-to-severe baseline symptomatology in two studies. Based on the overall findings from these trials, lifitegrast shows promise as a new treatment option for signs and symptoms of DED. 相似文献